黄芩汤抗 TNBS诱导的小鼠溃疡性结肠炎活性研究

目的：研究黄芩汤水煎液中主要成分及对2,4,6－三硝基苯磺酸钠（ TNBS）造模balb／c小鼠的溃疡性结肠炎的作用。方法 HPLC－MS法分析水煎液成分。雄性balb／c小鼠随机分为空白对照组,TNBS模型组,柳氮磺嘧啶阳性对照组（500 mg · kg－1）,黄芩汤水煎液1,2,4 g· kg－1治疗组。 TNBS造模7 d后,研究各组小鼠的结肠病理评分、微观评分、体质量、小鼠结肠长度和血清髓过氧化物酶（ MPO）。结果与标准品对照,黄芩汤水煎液中含有复方中主要成分,黄芩汤水煎液可使TNBS造模balb／c小鼠的体质量明显增加,改善身体的一般状况和小鼠结肠黏膜的损伤,下调MPO。结论黄芩汤水煎液中含有各药物的主要成分,对TNBS诱导的小鼠溃疡性结肠炎具有较好的治疗作用。     

隔药灸脐联合补中益气汤治疗肛肠术后并发症的临床观察

目地探讨隔药灸脐联合补中益气汤治疗肛肠术后并发症的疗效。方法选取2013年9月1日至2014年11月1日来安徽省针灸医院肛肠科的患者120例,随机分为三组,每组40例,即灸脐组（隔药灸脐组）、药物组（补中益气汤组）、灸药联合组（隔药灸脐＋补中益气汤）,观察三组的术后情况,并作数据统计。结果灸脐组治愈10例,好转18例,无效12例,总有效率70％;药物组治愈13例,好转16例,无效11例,总有效率72．5％;灸药联合组治愈20例,好转15例,无效5例,总有效率87．5％。结论隔药灸脐联合补中益气汤在治疗肛肠术后并发症方面疗效显著,有统计学意义（P ＜0．05）,值得临床推广。     

Clinical Yi-guan decoction for liver cirrhosis: A protocol for systematic review and meta analysis

Background:At present, Liver Cirrhosis (LC) is common in most later liver and gallbladder diseases that its morbidity and mortality seriously affect human health. The limitation and effectiveness of western medicine on LC have become a huge clinical challenge. However, a large number of clinical studies have shown that Yi-guan decoction has become a complementary treatment for LC. Therefore, this systematic review will aim to explore the safety and feasibility of Yi-guan decoction in the treatment of LC.Methods:We will conduct a comprehensive literature search in Medline, PubMed, Cochrane Database of Systematic Reviews, Embase, Chinese Biomedical Literatures Database, China National Knowledge Infrastructure, Wang Fang Database, Chinese Scientific Journal Database from inception to December 2020 without any language restriction, In addition, relevant literature will be searched manually. The main subject terms searched: “Yi-guan decoction” “cirrhosis” “LC”. Data entry will be performed by 2 researchers separately. Primary outcomes will be concluded: Liver function indicators: Total bilirubin, Alanine transaminase, Aspartate aminotransferase, etc. Secondary outcome indicators: Total effective rate, Nutrition index, Survival analysis, Adverse events; All randomized controlled trials collected in this study will be evaluated and rated using the Cochrane risk-of-biasassessment tool. Meta-analysis will be performed using RevMan 5.4.0 software. The heterogeneity test will be conducted between the studies, P < .1 and I² > 50% are the thresholds for the tests. Using solid effect model or random effect model will be based on its heterogeneity value.Results:This systematic review provides a theoretical basis for Yi-guan decoction to treat LC, we will report this result soon.Conclusion:This study will explore Yi-guan decoction can will be used as one of the non drug therapies to prevent or treat LC.Trial registration number:INPLASY2020120114.     

Efficacy and safety of Buzhong Yiqi decoction combined with western medicine in the treatment of myasthenia gravis: A protocol for systematic review and meta-analysis

Background:Myasthenia gravis is a common autoimmune disease in clinic. Although there are various ways and drugs for the treatment of myasthenia gravis in Western medicine, there are still a variety of adverse reactions. Studies have shown that Buzhong Yiqi decoction combined with Western medicine has a certain efficacy in the treatment of myasthenia gravis, but there is a lack of evidence-based medicine. The research carried out in this scheme is to systematically evaluate the efficacy and safety of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis, and to provide reliable evidence for guiding clinical practice.Methods:English databases (the Cochrane Library, PubMed, Web of Science, Embase) and Chinese databases (China Biomedical Database, China Science and Technology Journal Database, China National Knowledge Infrastructure, Wanfang) will be searched by computer. In addition, Baidu Academic and Chinese Clinical Trial Registration Center will be searched manually. A randomized controlled clinical trial of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis will be conducted from the establishment of the database to December 2020. The 2 researchers independently carry out data extraction and literature quality evaluation on the quality of the included study, and meta-analysis of the included literature will be carried out by using RevMan 5.3 software.Results:This study will evaluate the efficacy and safety of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis by Quantitive MGscore, the number of Tregs cells and the content of anti-acetylcholine receptor antibody (AchR-Ab).Conclusion:This study will provide reliable evidence-based evidence for the clinical application of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis.Ethics and dissemination:Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences.OSF Registration number:DOI 10.17605/OSF.IO/MXUPK.     

清肠凉血方保留灌肠合美沙拉嗪对溃疡性结肠炎的影响

观察清肠凉血方保留灌肠治疗溃疡性结肠炎(UC)患者的临床疗效。方法:将符合纳入标准的60例UC患者采用平行对照随机单盲法分为治疗组(清肠凉血方保留灌肠联合口服美沙拉嗪治疗)及对照组(口服美沙拉嗪治疗)各30例。治疗持续6周,对临床有效病例随访6个月。结果:治疗组总有效率为93.3%,明显优于对照组的70.0%(P0.05);治疗后,治疗组主要临床症状评分及肠镜下黏膜疗效评分均低于对照组(P0.05);治疗组6个月内复发率显著低于对照组(P0.05)。结论:清肠凉血方保留灌肠联合口服美沙拉嗪治疗溃疡性结肠炎患者临床疗效显著,可明显降低临床复发率。     

中药正肝汤对乙型肝炎肝硬化患者血清瘦素、脂联素水平以及胰岛素抵抗影响的分析

目的 观察中药制剂正肝汤治疗乙型肝炎(乙肝)肝硬化患者对其血清瘦素(LEP)、脂联素(ADP)水平及胰岛素抵抗(IR)的影响。方法 将入选的66例乙肝肝硬化患者随机分为对照组(31例)和治疗组(35例), 其中对照组选用肌苷片和维生素C口服治疗, 治疗组在此基础上, 应用正肝汤治疗, 疗程为3个月, 测定治疗前后患者血清LEP、ADP水平及IR指数。结果 对照组血清LEP、ADP水平和IR指数与治疗前比较, 差异无统计学意义(P>0.05);治疗组血清LEP、ADP水平和IR指数较治疗前明显下降, 差异有统计学意义(P<0.05), 治疗组血清LEP和ADP水平与对照组比较, 差异有统计学意义(P<0.05)。结论 正肝汤治疗乙肝肝硬化患者具有降低血清LEP、ADP水平, 并有改善IR的作用。     

养心定悸方治疗心房颤动的疗效观察

目的观察养心定悸方治疗心房颤动的疗效。方法 90例房颤患者随机分为两组。对照组予西医常规治疗,治疗组在此基础上应用养心定悸方。结果治疗组总有效率明显优于对照组(P0.05)。结论养心定悸方对房颤患者有较好的疗效。     

射干麻黄汤对哮喘患者气道高反应性的影响

目的观察射干麻黄汤对寒哮患者气道高反应性的影响。方法 51例轻、中度寒哮患者随机分为两组。对照组给予沙丁胺醇气雾剂,治疗组在对照组的基础上加用射干麻黄汤中药配方颗粒冲服,两组均治疗12周,分别于治疗前和治疗后进行哮喘控制测试评分(ACT评分)、最大呼气峰流速(PEF)、肺通气功能及支气管激发或舒张试验检测,并进行疗效判定。结果治疗组疗效优于对照组(P0.05),两组FEV1、FEV1%预计值、PEF均较治疗前显著改善(P0.05),而治疗组气道高反应性(支气管激发或舒张实验阳性率)及PEF变异率均较对照组下降(P0.05),ACT评分较对照组明显改善(P0.05)。结论射干麻黄汤能改善哮喘患者的症状及气道高反应性。     

观察自拟中药汤剂联合西药治疗骨质疏松的临床疗效及其对骨代谢生化指标和血中骨钙素的影响

目的观察自拟中药汤剂联合西药治疗骨质疏松的临床疗效及其对骨代谢生化指标和血中骨钙素的影响。方法 124例骨质疏松患者随机分为两组。对照组用西药治疗,治疗组在对照组基础上结合自拟中药汤剂治疗。1个月后对两组疗效及相关指标进行观察。结果治疗组治疗后总有效率显著高于对照组(P0.05);治疗组治疗后U-Ca、ALP与对照组比较具有显著性差异(P0.05);治疗组治疗后血中骨钙素明显高于对照组(P0.05);两组患者在治疗过程中均未出现明显不良反应。结论自拟中药汤剂联合西药治疗骨质疏松患者效果显著。